University of Bern spinout Arctos Medical has been acquired by existing shareholder Novartis.

Arctos Medical, a Switzerland-based developer of gene therapies to restore sight that was spun out of University of Bern, was acquired by pharmaceutical firm Novartis for an undisclosed amount today.
Founded in 2012, Arctos Medical is working on optogenetics-based adeno-associated virus gene therapies to treat diseases that involve photoreceptor loss – causing blindness – such as inherited retinal dystrophies and age-related macular degeneration.
The technology was developed by Arctos’ scientific co-founders Sonja Kleinlogel and Michiel van Wyk.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).